Replies to post #4610 on Cytodyn Inc (CYDY)

[TheBioTechG]

With respect to monotherapy and the last CC, Dr. Nader stated that the FDA requested that they tweak their protocol, which is an understandable delay.

With respect to the adjunct trial, they have a number of different sites across the US where they can conduct their trials, and enough people with HIV (CCR5 tropic) to fill them. The majority of HIV patients and the vast majority of newly infected have the CCR5 tropism - so it definitely makes one wonder why it's taking this long. It's been a question I've asked myself as well. I would have figured that at least adjunct would have filled up by now. Hopefully tomorrows CC brings positive news on this front.

[misiu143]

There are specification from FDA , what type ( medically )of patients one can accept for any study.